John P. Hamill - 31 Mar 2026 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Reporting relationship: SrVP/CFO/Prin Fin & Acct Ofcr
Issuer ticker: APRE
Reported as of: 31 Mar 2026
Net transaction value: +$24,999
SEC form: 4
Accepted by SEC: 01 Apr 2026, 16:15:55 UTC
Prior SEC filing: 16 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ John Hamill

Key filing fact

John P. Hamill filed Form 4 for Aprea Therapeutics, Inc. (APRE) on 01 Apr 2026.

Key facts

This page summarizes John P. Hamill's Form 4 filing for Aprea Therapeutics, Inc. (APRE).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 01 Apr 2026, 16:15.

Change

Previous filing in this sequence was filed on 16 Mar 2026.
Current net transaction value: +$24,999.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001716213 Primary reporting owner

Hamill John P.

Relationship: SrVP/CFO/Prin Fin & Acct Ofcr
Address: 3805 OLD EASTON ROAD, DOYLESTOWN
Signature: /s/ John Hamill
Signature date: 01 Apr 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

APRE transaction Derivative

Pre-Funded Warrant

Purchase

Transaction value: $24,999
Shares: +30,978
Change %
Price: $0.8070
Shares after: 30,978
Date: 31 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 30,978
Exercise price: $0.001000
Footnotes: F1, F2

APRE transaction Derivative

Common Warrant

Purchase

Transaction value
Shares: +30,978
Change %
Price
Shares after: 30,978
Date: 31 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 30,978
Exercise price: $0.6830
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

On March 30, 2026, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement which closed on March 31, 2026, (i) pre-funded warrants ("Pre-Funded Warrants") to purchase up to an aggregate of 30,978 shares of the Issuer's common stock ("Shares") at a purchase price of $0.808, less the $0.001 exercise price, per Pre-Funded Warrant and (ii) accompanying common warrants ("Common Warrants") to purchase up to an aggregate of 30,978 Shares.

Footnote F2

The Pre-Funded Warrants are immediately exercisable at any time after the date of issuance. Pursuant to the terms of the Pre-Funded Warrants, the Pre-Funded Warrants cannot be exercised to the extent that, upon giving effect to or immediately prior to such exercise, would cause either (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) would exceed 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise or (ii) the combined voting power of the Issuer's securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the combined voting power of all of the Issuer's securities outstanding immediately after giving effect to the exercise (the "Beneficial Ownership Limitation")

Footnote F3

The Common Warrants are immediately exercisable, subject to the Beneficial Ownership Limitation. The Common Warrants will expire on the earlier of (ii) December 31, 2029, and (ii) 30 calendars days after the date upon which the Pre-Funded Warrant is exercised, proportional to the amount of such exercise.